SCHEMBL16187973

SCHEMBL16187973

O=S(=O)(Nc1ccc(O)c2ncccc12)c1ccc2ccccc2c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 7/20 0.73
MMP9 P14780 1/20 0.69
TDP1 Q9NUW8 5/20 0.67
KDM4E B2RXH2 4/20 0.67
NPC1 O15118 2/20 0.67
ALDH1A1 P00352 1/20 0.67
GAA P10253 1/20 0.67
HTT P42858 1/20 0.67
GFER P55789 1/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
MEN1 O00255 6/20 0.66
KMT2A Q03164 6/20 0.66
GLO1 Q04760 1/20 0.66
UQCRB P14927 1/20 0.65
AGTR1 P30556 1/20 0.64
POLB P06746 1/20 0.58
PKM P14618 1/20 0.56
SLC40A1 Q9NP59 1/20 0.53
HSP90AA1 P07900 1/20 0.49
RAB9A P51151 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3260612 0.83 HKDC1 (0.66) ALDH1A1GAAGFERSMN1; SMN2MEN1
SCHEMBL16187967 0.83 MMP2 (1.00) MMP2MMP9TDP1KDM4ENPC1
SCHEMBL26241643 0.81 TDP1 (0.97) MMP2MMP9TDP1KDM4ENPC1
SCHEMBL6979087 0.80 TDP1 (1.00) TDP1ALDH1A1HTTMEN1KMT2A
SCHEMBL17962342 0.79 COMT (0.67) MMP2TDP1KDM4EMEN1KMT2A
SCHEMBL16187968 0.79 UQCRB (1.00) MMP2MMP9TDP1KDM4ENPC1
SCHEMBL22076981 0.78 MEN1 (1.00) TDP1HTTSMN1; SMN2MEN1KMT2A
SCHEMBL416258 0.76 MEN1 (0.73) TDP1SMN1; SMN2MEN1KMT2AGLO1
SCHEMBL13509965 0.76 MEN1 (0.83) MMP2TDP1KDM4EALDH1A1GAA
SCHEMBL3260752 0.75 MEN1 (0.62) TDP1ALDH1A1GAAHTTGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9371286-B2 Pharmaceutical composition with enhanced efficacy for inhibiting angiogenesis INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2016-06-21 US disclosed
US-9371286-B2 Pharmaceutical composition with enhanced efficacy for inhibiting angiogenesis INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2016-06-21 US disclosed
US-20140315947-A1 PHARMACEUTICAL COMPOSITION WITH ENHANCED EFFICACY FOR INHIBITING ANGIOGENESIS INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2014-10-23 US disclosed
US-20140315947-A1 PHARMACEUTICAL COMPOSITION WITH ENHANCED EFFICACY FOR INHIBITING ANGIOGENESIS INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2014-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315947-A1 PHARMACEUTICAL COMPOSITION WITH ENHANCED EFFICACY FOR INHIBITING ANGIOGENESIS UQCRB, UQCRC1, UQCRC2 MMP2 2721/4885MMP9 3879/4885TDP1 4207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.